Skip to main content
. Author manuscript; available in PMC: 2016 Apr 19.
Published in final edited form as: Nature. 2014 Nov 27;515(7528):563–567. doi: 10.1038/nature14011

Figure 2. Antitumour activity of MPDL3280A.

Figure 2

a, A waterfall plot of patients with non-small cell lung cancer (NSCLC) measuring the maximum reduction from baseline in the sum of the longest diameter (SLD) for target lesions; 120% and 230% are marked by dashed lines. b, The time to response (Response Evaluation Criteria in Solid Tumours version 1.1) and the duration of study treatment for patients with NSCLC. The patient with progressive disease (PD) experienced ongoing clinical benefit as judged by the investigator. All but one response was confirmed. c, A waterfall plot of patients with all tumour types measuring the maximum reduction from baseline in the SLD for target lesions; 120% and 230% are marked by dashed lines. IC, tumour-infiltrating immune cells; IHC, immunohistochemistry; RCC, renal cell carcinoma.